Section - CAP Smart Takes

01. Psychosocial Functioning in Transgender Youth After 2 Years of Hormones

Published on September 1, 2023 Certification expiration date: September 1, 2026

David R. Rosenberg, M.D.

Chair of the Department of Psychiatry & Behavioral Neuroscience - Wayne State University School of Medicine

Key Points

Youth treated with gender-affirming hormones showed significant improvements in depressive symptoms, anxiety, life satisfaction, and appearance congruence over a 2-year period.
However, the study's limitations, particularly the absence of a comparison group, could affect confidence in its results.

To unlock this audio you need to become a Silver, Gold, Silver extended or Gold extended Member.

Check Our CME Program

Downloads for Offline Access

Download Audio File (MP3)

Text version

Greetings. This is David Rosenberg from the Psychopharmacology Institute. In this Child and Adolescent Psychiatry Smart Take, we closely examine the impact of gender-affirming hormones—testosterone and estradiol—on transgender and nonbinary youth. This area requires urgent familiarity for clinicians; the role of psychiatrists is expanding due to documented mental health disparities within this demographic.

In recent years, transgender and binary youth constituted 2%–9% of high school–aged adolescents in the United States. Transgender and nonbinary youth may experience increased gender dysphoria due to a mismatch between gender identity and physical appearance. A rising number of these youth are receiving treatment to alleviate gender dysphoria and enhance psychosocial functioning by promoting gender-congruent secondary sex characteristics and inhibiting incongruent pubertal development.

The authors studied 315 transgender and nonbinary individuals aged 12–20 over 2 years. Notably, over 60% of the participants were transmasculine. Nonbinary participants, comprising 65% identified as female at birth, were underrepresented. This

Unlock this CAP Smart Take and earn 0.50 CMEs
Become a Silver, Gold, Silver extended or Gold extended Member.

Get Instant Access

Already have an account? Sign in

Next Section

02. Risk of Major Malformations Following First-Trimester Exposure to Olanzapine

Learning Objectives:

Learn effective strategies for evaluating, monitoring, and managing antidepressant-related side effects in young patients.
Understand the impact of age on antidepressant response in patients with major depressive disorder and its implications for clinical practice.
Recognize that lamotrigine appears to be effective in pediatric mood disorders as monotherapy or an augmenting agent.
Recognize that ADHD with comorbid anxiety requires distinct diagnostic and treatment approaches.
Understand the real-world prescribing patterns of OROS-MPH in treating ADHD in children and adolescents.

Original Release Date: September 1, 2023

Review and Re-release Date: March 1, 2024

Expiration Date: September 1, 2026

Expert: David Rosenberg, M.D.

Medical Editor: Melissa Mariano, M.D.

Relevant Financial Disclosures:

None of the faculty, planners, and reviewers for this educational activity have relevant financial relationships to disclose during the last 24 months with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Contact Information: For questions regarding the content or access to this activity, contact us at support@psychopharmacologyinstitute.com

Instructions for Participation and Credit:

Participants must complete the activity online during the valid credit period that is noted above.

Follow these steps to earn CME credit:

View the required educational content provided on this course page.
Complete the Post Activity Evaluation for providing the necessary feedback for continuing accreditation purposes and for the development of future activities. NOTE: Completing the Post Activity Evaluation after the quiz is required to receive the earned credit.
Download your certificate.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of Medical Academy LLC and the Psychopharmacology Institute. Medical Academy is accredited by the ACCME to provide continuing medical education for physicians

Credit Designation Statement

Medical Academy designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.